What Are the Risk Management File Requirements for Medical Device Registration in Vietnam?

In short: Before discussing which risk management documents to submit, a manufacturer should first confirm the target market, the product risk classification, the applicable regulatory pathway and the documentation already available. Only then can the technical file, quality management system evidence, labels and instructions for use, local authorised representation, clinical evidence and post-market maintenance requirements be properly assessed. AIMEILI advises completing a documentation gap assessment before formal submission, so that unclear classification, incomplete evidence or undefined authorisation arrangements do not extend the registration timeline.

Published: 10 July 2026  |  Updated: 10 July 2026

Key Takeaways

The question of what Vietnamese registration requires for risk management documentation should be addressed through a structured regulatory review rather than a simple document list. Companies should identify the product risk class and submission route, then evaluate the technical file, quality system, labelling and IFU, local agent, clinical evidence and post-market maintenance obligations together.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Vietnam registration typically affects the technical file, authorised representation, importer coordination, label language, quality system evidence and subsequent change maintenance at the same time. If a project is managed purely as a question of which documents to hand over, correction requests and rework frequently arise in model coverage, evidence chain consistency, label claims and certificate control.

AIMEILI recommends positioning this question within a broader GHWP member state and multi-country market access strategy, using one reusable core technical file to support localisation in different markets, rather than rebuilding documentation from scratch for each country.

Applicable Scenarios and Core Questions

Companies searching for information on Vietnamese registration risk management documentation are usually not looking for a conceptual explanation. They need to judge whether existing documentation can support a Vietnamese submission, whether a local agent or authorised representative is required, why timelines are being extended, and which issues could affect the launch plan. Behind this question there are typically several linked topics: product classification, registration pathway, evidence chain, label localisation and post-market maintenance responsibility.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering a single country's procedure is not sufficient. A more valuable approach is to prepare reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labelling, and then localise them according to each country's regulatory requirements.

Registration Assessment Logic

Companies should first confirm the intended use, mechanism of action, use environment, mode and duration of body contact, sterility, whether the device is active, and whether it contains software or has IVD characteristics. The risk class and submission route can then be determined. Once the route is wrong, the subsequent translation, notarisation, authorisation, testing and supplementary documentation all move in the wrong direction.

For a Vietnamese project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who handles regulatory communication, who manages importation and post-market events, who triggers changes, and who maintains renewal documentation. If these points are left ambiguous in a commercial contract, control over the market can be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, the technical file, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labels and instructions for use, authorisation documents, existing registration certificates, manufacturer declarations and post-market surveillance materials.

The critical factor in documentation quality is not volume but consistency. IFU claims, the model coverage of test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must all support one another. Regulators focus on whether the device is safe, effective and traceable for its intended purpose, not on how many files have been uploaded.

Risk management documentation deserves particular attention. It should demonstrate a continuous process covering hazard identification, risk analysis, risk control measures, verification of the effectiveness of those controls, evaluation of residual risks and benefit-risk conclusions, and it is commonly structured in line with ISO 14971. The risk management file must be traceable to the design and manufacturing information, the verification and validation reports, the clinical evaluation and the labelling, because inconsistencies between these documents are a frequent source of correction requests.

Common Errors

The most common problem is treating registration as a simple document submission exercise without first clarifying product classification, evidence coverage and local responsibility relationships.

• Translating NMPA documentation directly and submitting it, without reorganising the evidence according to the Vietnamese pathway.
• Listing too many models and specifications while test reports, clinical evidence or labelling do not cover them adequately.
• Selecting a local agent solely on commercial sales grounds, without defining regulatory responsibility, certificate control and post-market maintenance duties.
• Inconsistency between labels, IFU, promotional materials and registration claims, leading to correction requests or post-market compliance risk.
• Failing to plan multi-country document reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting the project, companies should use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management documentation, clinical evaluation and English-language IFU.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorised representative.
• Establish a target-country gap assessment table identifying what must be re-tested, translated, notarised or supported by additional declarations.

AIMEILI's Perspective

AIMEILI advises companies not to treat Vietnamese registration as a one-off document submission but to manage it as an overseas market access programme. For companies entering multiple countries, building a clear core technical file and evidence matrix first and then converting it to national requirements is usually faster, more stable and more conducive to subsequent changes and renewals than filling documentation gaps on a country-by-country basis.

From a project management perspective, three matters should be controlled in advance: first, product classification and pathway determination; second, the consistency of the documentation evidence chain; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, a project can still encounter repeated issues during correction requests, agent communication and post-market maintenance, regardless of how many documents appear to have been prepared.

Frequently Asked Follow-up Questions

Can domestic documentation be used directly for Vietnamese registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as-is. Companies need to adjust the document structure, language, labelling, authorisation documents and evidence chain in accordance with local regulatory requirements, and re-verify that the risk management documentation, test reports and clinical evidence remain internally consistent after that restructuring.

When is the best time to start the gap assessment?

Immediately after the target market and product list are confirmed. The earlier the gap assessment is completed, the easier it is to schedule re-testing, translation, label adjustment and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals and post-market event handling. Unclear rights and responsibilities can affect certificate control and the stability of the market after approval.

Project Execution Recommendations

When executing this type of registration project, companies should set up a project tracker that manages the product list, model and specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This allows documentation gaps to be identified promptly and enables management to judge whether the project will affect the launch plan.

Companies that already hold registrations in several countries should also build an evidence reuse matrix, clarifying which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. Labels and IFU, clinical evaluation, risk management, performance verification and quality system certificates in particular must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Define the local agent's role and certificate control.
• Track translation, notarisation, testing and correction status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent. If the scope of the ISO 13485 certificate does not match the products being registered, or if the manufacturing site, model specifications or IFU version do not match the test reports, additional clarification may be requested even when a large volume of documentation has been prepared.

Companies should create an evidence consistency checklist before submission, mapping product name, model and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version, and the quality system certificate item by item. This step appears basic but can significantly reduce the probability of correction requests, particularly for projects involving multiple GHWP member states or multiple product families submitted at the same time.

Localisation Conversion and Agent Responsibilities

Vietnamese registration projects typically involve arrangements with a local agent, authorised representative, importer or registration holder. Companies need to confirm in advance whether the local partner is responsible only for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and post-market stability.

Labels, IFU and authorisation documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorised representative details and after-sales contact information. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localisation conversion is to transform reusable evidence into a submission structure acceptable in the target country, rather than writing an isolated new set of documents.

Post-Market Maintenance and Long-Term Planning

Registration approval does not mean the compliance work is finished. Companies must also maintain certificate validity, change records, distributor authorisations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance, and later encounter a disconnect between the certificate and actual market sales when a manufacturing site changes, a model is added, the IFU is updated or the agent is replaced.

AIMEILI recommends managing this topic within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, correction, post-market maintenance and renewal milestones. The value of this approach is not only higher efficiency for a single country's registration, but the development of a replicable go-global compliance capability that reduces the cost of starting from zero each time a new market is entered.

Further Reading

• Previous: How Are Multiple Device Models Grouped for Registration in Vietnam?
• Next: How Should Performance Verification Documentation Be Prepared for Vietnamese Registration?
• How Should Registration Documentation Be Prepared for Medical Device Registration in Malaysia?
• How Is Product Classification Determined for Medical Device Registration in Malaysia?
• How Should the Technical File Be Organised for Medical Device Registration in Malaysia?
• How Should Labels and Instructions for Use Be Localised for Medical Device Registration in Malaysia?
• How Should Clinical Evaluation Documentation Be Prepared for Medical Device Registration in Malaysia?
• Can Test Reports Be Reused for Medical Device Registration in Malaysia?

Content Review and Scope of Applicability

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: priority is given to official regulatory authorities, international organisations, standards organisations and publicly available regulatory materials; industry media and project experience are used only as supporting references.

Scope of applicability: this article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice. Specific projects should be based on the latest requirements of the target country's regulator and the actual documentation base of the product.